002030 达安基因
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-4.6091.03758.03462.27580.165
总资产报酬率 ROA (%)-3.7760.81243.13742.47647.733
投入资产回报率 ROIC (%)-4.4040.99154.96755.86861.803

边际利润分析
销售毛利率 (%)41.21950.46772.84274.76570.152
营业利润率 (%)-118.57110.29952.54253.82655.045
息税前利润/营业总收入 (%)-127.3283.28551.53453.35554.885
净利润/营业总收入 (%)-99.3176.07445.05647.21245.871

收益指标分析
经营活动净收益/利润总额(%)11.33041.799108.47898.63690.534
价值变动净收益/利润总额(%)70.759360.6295.5943.28515.033
营业外收支净额/利润总额(%)0.269-7.122-0.163-0.129-1.282

偿债能力分析
流动比率 (X)4.1533.0852.9542.3742.096
速动比率 (X)3.9492.9462.8292.1781.943
资产负债率 (%)13.89016.88921.28625.8940.326
带息债务/全部投入资本 (%)1.5264.1502.0725.89311.780
股东权益/带息债务 (%)6,346.1322,273.6244,656.1781,563.747728.301
股东权益/负债合计 (%)600.166477.214359.775274.665195.327
利息保障倍数 (X)15.091-0.519-55.909-132.714102.343

营运能力分析
应收账款周转天数 (天)841.967933.39894.51888.19074.352
存货周转天数 (天)190.283187.44447.49975.33256.534